Teva Focuses on Central Nervous System, Respiratory Drugs

Teva Pharmaceutical Industries Ltd. will focus drug-development efforts under new Chief Executive Officer Jeremy Levin on respiratory and central nervous system illnesses as the company seeks to replace medicines set to lose patent protection in the next three years.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.